Opendata, web and dolomites

CardioReGenix SIGNED

CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CardioReGenix project word cloud

Explore the words cloud of the CardioReGenix project. It provides you a very rough idea of what is the project "CardioReGenix" about.

harnessing    vii    preclinical    grade    ema    efficient    disciplinary    risk    undertaking    reducing    platforms    latest    million    involvement    17    people    competitive    rare    strategy    cvd    allowed    treatment    expression    man    regulation    mainly    innovative    deeper    cellular    ischemia    atmp    mechanisms    generation    diseases    momentum    molecular    authorization    prospect    31    refine    optimizing    worldwide    vector    patients    clinical    technological    implementing    successfully    liaising    preliminary    atmps    gmp    maximizing    cardiac    adverse    business    monogenetic    gains    data    innovations    impacted    heart    cardiology    conventional    strengthen    progress    die    disease    therapy    manufacturing    significantly    validate    cardiovascular    who    translation    sme    treating    overcome    marketing    bottlenecks    vitro    gene    myocardial    safer    models    therapeutic    first    valorization    vectors    incremental    gained    suffering    position    cardioregenix    deaths    estimates    vi    treatments    immune    gain   

Project "CardioReGenix" data sheet

The following table provides information about the project.

Coordinator
VRIJE UNIVERSITEIT BRUSSEL 

Organization address
address: PLEINLAAN 2
city: BRUSSEL
postcode: 1050
website: www.vub.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 14˙839˙773 €
 EC max contribution 14˙839˙773 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VRIJE UNIVERSITEIT BRUSSEL BE (BRUSSEL) coordinator 1˙987˙859.00
2    FINVECTOR OY FI (KUOPIO) participant 1˙601˙405.00
3    ITA-SUOMEN YLIOPISTO FI (KUOPIO) participant 1˙564˙156.00
4    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) participant 1˙411˙526.00
5    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 1˙356˙501.00
6    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 1˙193˙622.00
7    STICHTING VUMC NL (AMSTERDAM) participant 1˙106˙750.00
8    KING'S COLLEGE LONDON UK (LONDON) participant 1˙013˙675.00
9    CARDIOR PHARMACEUTICALS GMBH DE (HANNOVER) participant 908˙249.00
10    POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA FI (KYS) participant 890˙640.00
11    BATAVIA BIOSCIENCES BV NL (LEIDEN) participant 776˙507.00
12    A2F ASSOCIATES LIMITED UK (NEWMARKET) participant 718˙845.00
13    ASPHALION SL ES (BARCELONA) participant 310˙035.00

Map

 Project objective

WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress with conventional treatments is making incremental gains, there remains a need to develop innovative therapeutic approaches. Gene therapy has gained significant momentum, mainly for treatment of rare monogenetic diseases. Marketing authorization for gene therapy products has not impacted diseases such as CVD. Recent, deeper understanding of the molecular/cellular mechanisms of CVD and technology associated with more efficient and safer gene therapy vectors has allowed new opportunities for development of next-generation ATMPs for CVD. CardioReGenix focuses on technological innovations for the treatment of CVD, in particular heart failure and myocardial ischemia. We aim to overcome bottlenecks in gene therapy for CVD by (i) maximizing cardiac-specific gene expression; (ii) maximizing cardiac-specific gene delivery; (iii) reducing adverse immune responses; (iv) optimizing manufacturing for research and clinical-grade ATMPs ; (v) validate new promising targets using in vitro and preclinical models; (vi) undertaking first-in-man studies; (vii) developing and implementing an exploitation and valorization strategy with strong EU SME involvement. CardioReGenix is a high risk/high gain project supported by robust preliminary data and multi-disciplinary consortium harnessing know-how in vector development, GMP manufacturing, preclinical and clinical cardiology, regulation of ATMP and liaising with EMA, business development and clinical translation. CardioReGenix will (i) strengthen Europe's competitive position in gene therapy development for CVD; (ii) improve the prospect of successfully treating patients suffering from CVD by gene therapy and (iii) develop and refine the latest gene therapy platforms that go significantly beyond the state of the art.

 Publications

year authors and title journal last update
List of publications.
2019 Dongchao Lu, Thomas Thum
RNA-based diagnostic and therapeutic strategies for cardiovascular disease
published pages: , ISSN: 1759-5002, DOI: 10.1038/s41569-019-0218-x
Nature Reviews Cardiology 2019-08-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOREGENIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDIOREGENIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More